Considerations for Use of Immune Therapy to Treat mCRC

PROGRAM DESCRIPTION Colorectal cancer (CRC) is a leading cause of cancer-related deaths with poor 5-year survival rates for patients with metastatic disease. Patients with DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) ...

PROGRAM DESCRIPTION
Colorectal cancer (CRC) is a leading cause of cancer-related deaths with poor 5-year survival rates for patients with metastatic disease. Patients with DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) are a distinct biomarker-defined population who may benefit less from conventional therapy compared with patients with MMR-proficient/microsatellite stable mCRC. Treatment with antiprogrammed death-1 (PD-1) checkpoint inhibitors in patients with dMMR/MSI-H status has shown significant benefit in a number of clinical trials. Appropriate use of anti-PD-1 checkpoint inhibitors requires that clinicians perform accurate mismatch repair or MSI testing in patients with CRC and remain well informed of the efficacy and safety of immune therapy in this setting.

EDUCATIONAL OBJECTIVES
After participating in this activity, the participant will demonstrate the ability to:DISTINGUISH mCRC pathophysiology as well as the role of the immune system in relation to immunotherapeutic mCRC treatment.SUMMARIZE recently-approved and late-stage development mCRC immunotherapies.INCORPORATE new and emerging immunotherapies into mCRC treatment paradigms.The Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing take responsibility for the content, quality, and scientific integrity of this CME/CNE activity.

---

Write the first review

Resource tags